Literature DB >> 16966704

Antiangiogenic therapy in human gastrointestinal malignancies.

J Heidemann1, D G Binion, W Domschke, T Kucharzik.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16966704      PMCID： PMC1856413          DOI： 10.1136/gut.2005.088229

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  218 in total

1.  Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells.

Authors:  Rosalba Salcedo; Xia Zhang; Howard A Young; Nelson Michael; Ken Wasserman; Wei-Hong Ma; Manuela Martins-Green; William J Murphy; Joost J Oppenheim
Journal:  Blood       Date:  2003-06-05       Impact factor: 22.113

Review 2.  Angiopoietins in angiogenesis and beyond.

Authors:  Stelios Tsigkos; Micheal Koutsilieris; Andreas Papapetropoulos
Journal:  Expert Opin Investig Drugs       Date:  2003-06       Impact factor: 6.206

3.  Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer.

Authors:  Lissandra Dal Lago; Marc F Richter; Anna I Cancela; Sabrina A Fernandes; Keylla T Jung; Ana C Rodrigues; Teresa Dalla Costa; Luciane P Di Leone; Gilberto Schwartsmann
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

4.  Clinical significance of thrombospondin-1 expression in relation to vascular endothelial growth factor and interleukin-10 expression at the deepest invasive tumor site of advanced colorectal carcinoma.

Authors:  Eijiro Kaio; Shinji Tanaka; Shiro Oka; Toru Hiyama; Yasuhiko Kitadai; Ken Haruma; Kazuaki Chayama
Journal:  Int J Oncol       Date:  2003-10       Impact factor: 5.650

5.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

Authors:  James C Yang; Leah Haworth; Richard M Sherry; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Seth M Steinberg; Helen X Chen; Steven A Rosenberg
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

6.  Combination therapy with paclitaxel and thalidomide inhibits angiogenesis and growth of human colon cancer xenograft in mice.

Authors:  Toshiyuki Fujii; Mitsuo Tachibana; Dipok Kumar Dhar; Shuhei Ueda; Shoichi Kinugasa; Hiroshi Yoshimura; Hitoshi Kohno; Naofumi Nagasue
Journal:  Anticancer Res       Date:  2003 May-Jun       Impact factor: 2.480

7.  Thrombin induces angiogenesis and vascular endothelial growth factor expression in human endothelial cells: possible relevance to HIF-1alpha.

Authors:  E Dupuy; A Habib; M Lebret; R Yang; S Levy-Toledano; G Tobelem
Journal:  J Thromb Haemost       Date:  2003-05       Impact factor: 5.824

Review 8.  Targeting HIF-1 for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

9.  Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients.

Authors:  Matthew G Tutton; Mark L George; Suzanne A Eccles; Sarah Burton; R Ian Swift; A Muti Abulafi
Journal:  Int J Cancer       Date:  2003-11-20       Impact factor: 7.396

Review 10.  Surrogate markers in antiangiogenesis clinical trials.

Authors:  D W Davis; D J McConkey; J L Abbruzzese; R S Herbst
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640
View more
  3 in total

1.  Curcumin suppresses invasiveness and vasculogenic mimicry of squamous cell carcinoma of the larynx through the inhibition of JAK-2/STAT-3 signaling pathway.

Authors:  An Hu; Jing-Juan Huang; Xiao-Jie Jin; Ji-Ping Li; Yuan-Jia Tang; Xin-Fang Huang; Hui-Juan Cui; Wei-Hua Xu; Guang-Bin Sun
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

2.  Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers.

Authors:  Florian Lordick; Dirk Jäger
Journal:  Gastrointest Cancer Res       Date:  2008-07

3.  Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition.

Authors:  D G Binion; M F Otterson; P Rafiee
Journal:  Gut       Date:  2008-07-02       Impact factor: 23.059
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.